Insider Buying: Electra Therapeutics (NASDAQ:ETRA) Director Buys $537,393.51 in Stock

Key Points

• Orbimed Advisors increased its Electra Therapeutics stake by buying 71,367 shares for about $537,394 at an average $7.53 apiece, bringing its ownership to roughly 5.19 million shares. The article also reports additional purchases of 156,091 shares on Nov. 5 and 245,113 shares on Nov. 3.
• Electra shares fell 7.8% to $7.35 in Thursday midday trading, near the reported 52-week low of $6.86.
• Analysts have a consensus Buy rating and a $33.50 consensus price target; reported targets include $36 from JPMorgan and $32 from Jefferies.

Electra Therapeutics, Inc. (NASDAQ:ETRA - Get Free Report) Director Orbimed Advisors Llc purchased 71,367 shares of the business's stock in a transaction on Wednesday, November 4th. The shares were acquired at an average cost of $7.53 per share, for a total transaction of $537,393.51. Following the completion of the transaction, the director directly owned 5,189,871 shares in the company, valued at approximately $39,079,728.63. This represents a 1.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, November 5th, Orbimed Advisors Llc acquired 156,091 shares of Electra Therapeutics stock. The shares were acquired at an average price of $7.31 per share, with a total value of $1,141,025.21.
• On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The stock was bought at an average price of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc acquired 1,333,333 shares of Electra Therapeutics stock. The stock was bought at an average price of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Down 7.8%

Shares of NASDAQ:ETRA traded down $0.62 during midday trading on Thursday, reaching $7.35. The company had a trading volume of 524,786 shares, compared to its average volume of 481,923. Electra Therapeutics, Inc. has a 1-year low of $6.86 and a 1-year high of $15.50.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. began coverage on Electra Therapeutics in a research note on Thursday, October 22nd. They issued an "overweight" rating and a $36.00 price target for the company. Wall Street Zen raised Electra Therapeutics to a "hold" rating in a research report on Saturday, September 26th. Jefferies Financial Group began coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They set a "buy" rating and a $32.00 price objective on the stock. Cantor Fitzgerald started coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued an "overweight" rating for the company. Finally, TD Cowen initiated coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Electra Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company's approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra's lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.